ABE44
Anti-trimethyl Histone H3 (Lys27) Antibody
from rabbit, purified by affinity chromatography
別名:
H3K27me3, Histone H3 (tri methyl K27), H3 histone family, member T, histone 3, H3, histone cluster 3, H3, H3K27me3
サイズを選択してください
| 容量 | カタログ番号 | 在庫状況 | 単価 |
|---|
この商品について
biological source
rabbit
Quality Segment
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
mouse, human
technique(s)
dot blot: suitable, immunocytochemistry: suitable, inhibition assay: suitable (peptide), western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
trimethylation (Lys27)
Gene Information
human ... HIST1H3F(8968)
General description
Immunogen
Application
ヒストン
ペプチド阻害アッセイ： この抗体により、HeLa細胞抽出物でペプチドが阻害されました。
エピジェネティクス・核内機能分子&
Biochem/physiol Actions
Physical form
Preparation Note
Analysis Note
ウェスタンブロッティング：0.1 µg/mLで使用、10 µgのHeLa酸抽出物中のヒストンH3を検出できます。
HeLa酸抽出物およびリコンビナントヒストンH3
Other Notes
Disclaimer
1 of 1
当該品目 | |||
|---|---|---|---|
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| antibody form affinity isolated antibody | antibody form affinity isolated antibody | antibody form affinity isolated antibody | antibody form affinity isolated antibody |
| biological source rabbit | biological source rabbit | biological source rabbit | biological source rabbit |
| technique(s) dot blot: suitable, inhibition assay: suitable (peptide), immunocytochemistry: suitable, western blot: suitable | technique(s) ChIP: suitable (ChIP-seq), dot blot: suitable, immunocytochemistry: suitable, western blot: suitable | technique(s) dot blot: suitable, western blot: suitable | technique(s) dot blot: suitable, immunohistochemistry: suitable, immunoprecipitation (IP): suitable, western blot: suitable |
| clone polyclonal | clone polyclonal | clone polyclonal | clone polyclonal |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
Still not finding the right product?
Explore all of our products under Anti-trimethyl Histone H3 (Lys27) Antibody
— または —
製品選択ツール}で選択肢を絞り込んでください。
保管分類
12 - Non Combustible Liquids
wgk
WGK 1
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
関連コンテンツ
Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| ABE44 | 04053252675270 |